Market Cap

PolyPeptide Group AG Market Capitalization:

CHF559.1 Million

CHF as of Jan. 1, 2024

US$664.2 Million

business PolyPeptide Group AG Company Profile

PolyPeptide Group AG Main Stock Listing

SIX: PPGN

Market Capitalization History of PolyPeptide Group AG

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Top Competitors by Market Capitalization

Industry: Drug Manufacturers—Specialty & Generic
Company Market Cap (USD)
Zoetis Inc. $89.09 B
MERCK Kommanditgesellschaft auf Aktien $67.64 B
Takeda Pharmaceutical Company Limited $47.71 B
Haleon plc $38.90 B
PPD, Inc. $16.58 B
Sector: Healthcare
Company Market Cap (USD)
Lilly $586.39 B
UnitedHealth Group $504.47 B
Novo Nordisk $461.52 B
Johnson & Johnson $387.50 B
Merck $296.51 B

Yearly evolution of PolyPeptide Group AG market cap

Date Market Cap YoY Change
Jan. 1, 2024 CHF559.1 M -38.50%
Jan. 1, 2023 CHF909.0 M -70.24%
Jan. 1, 2022 CHF3.05 B

Market capitalization is calculated from the opening stock price at the beginning of each year.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

PolyPeptide Group AG Categories

Switzerland languages Healthcare languages Drug Manufacturers—Specialty & Generic
Switzerland Healthcare Switzerland Drug Manufacturers—Specialty & Generic

Stocks & Indices

PolyPeptide Group AG has the following listings and related stock indices.


Stock: SIX: PPGN

What is a company's market capitalization?

The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.